---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Prevalence"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Prevalence. Topics: Annual prevalence of geographic atrophy in U.S. Medicare Advantage enrollees aged 65 years and older; Prevalence of geographic atrophy by age, race, and foveal involvement in U.S. Medicare Advantage claims; Prevalence of geographic atrophy in U.S. Medicare Advantage claims with a 24-month ascertainment window; Estimated number of people in the United States with geographic atrophy; 7 further topics. 11 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/prevalence"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Geographic atrophy secondary to age-related macular degeneration

<a id="topic-2.2.1.2.2-1"></a>

### Annual prevalence of geographic atrophy in U.S. Medicare Advantage enrollees aged 65 years and older

> “The total number of patients in the denominator was 2,175,803 (2018); 2,445,163 (2019); 2,680,322 (2020); and 2,905,366 (2021). The annual prevalence of GA was 0.56% (2018), 0.55% (2019), 0.48% (2020), and 0.51% (2021).”
> “The prevalence of GA was highest among individuals classified as White race (annual range 0.61% to 0.71%) and among patients with GA aged 75 years and older (range 0.95% to 1.11%). The proportion of patients with GA with co-occurring wet AMD was 25.6% to 28.0%.”

Source: [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/)

<a id="topic-2.2.1.2.2-2"></a>

### Prevalence of geographic atrophy by age, race, and foveal involvement in U.S. Medicare Advantage claims

> “The annual prevalence for GA without SFI was 0.21% to 0.25% across the assessment years”
> “The annual prevalence for GA with SFI was 0.27% to 0.31% during the same period. The annual prevalence of GA also was estimated at the level of eyes, with bilateral GA prevalence between 0.24% and 0.29% and unilateral GA between 0.23% and 0.27% from 2018 to 2021.”
> “Among the individuals classified as Black race, annual prevalence ranged from 0.09% to 0.11%. The annual prevalence of GA was calculated for 2 age categories; it was higher among individuals aged 75 years and older (0.95% to 1.11%) compared with people aged younger than 75 years (0.15% to 0.18%).”

Source: [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/)

<a id="topic-2.2.1.2.2-3"></a>

### Prevalence of geographic atrophy in U.S. Medicare Advantage claims with a 24-month ascertainment window

> “In the sensitivity analyses, including an additional 12 months for measuring prevalence, the annual prevalence of GA increased: 0.85% (2018), 0.83% (2019), 0.77% (2020), and 0.74% (2021)”
> “The lower prevalence of GA observed in claims data relative to other studies warrants careful consideration; coding practices likely will evolve with new GA therapies on the market.”

Source: [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/)

<a id="topic-2.2.1.2.2-4"></a>

### Estimated number of people in the United States with geographic atrophy

> “Published studies estimate approximately 1 million people in the United States have GA in at least 1 eye.”

Source: [Saundankar et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695844/)

<a id="topic-2.2.1.2.2-5"></a>

### Late AMD in U.S. adults aged 40 years and older in 2019 (geographic atrophy and neovascular AMD combined)

> “We estimated there were 1.49 million people 40 years and older (95% UI, 0.97-2.15) living with late-stage AMD, corresponding to a crude prevalence rate of 0.94% (95% UI, 0.62-1.36).”
> “Prevalence of late-stage AMD increased with age from 0.02% (95% UI, 0.01-0.05) among those 40 to 44 years (Figure 3) to 11.39% (95% UI, 6.45-18.46) among people 85 years or older.”
> “late-stage (defined as choroidal neovascularization and/or geographic atrophy in either eye)”

Source: [Rein et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9634594/)

<a id="topic-2.2.1.2.2-6"></a>

### Late AMD in U.S. adults aged 40 years and older in 2000 (geographic atrophy and neovascular AMD combined)

> “The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% (95% confidence interval, 1.38%-1.55%), with 1.75 million citizens having AMD. The prevalence of AMD increased dramatically with age, with more than 15% of the white women older than 80 years having neovascular AMD and/or geographic atrophy.”

Source: [Friedman et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15078675/)

<a id="topic-2.2.1.2.2-7"></a>

### Global pooled prevalence of geographic atrophy by ancestry

> “Eight (21%) of the 39 studies provided information on geographic atrophy and neovascular subtypes.”
> “Subgroup analysis showed similar overall prevalence of geographic atrophy (0·44%, 95% CrI 0·15–1·36) and neovascular age-related macular degeneration (0·46%, 0·18–1·08).”
> “Europeans had a higher prevalence of geographic atrophy (1·11%, 95% CrI 0·53–2·08) than Africans (0·14%, 0·04–0·45), Asians (0·21%, 0·04–0·87), and Hispanics (0·16%, 0·05–0·46).”

Source: [Wong et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25104651/)

<a id="topic-2.2.1.2.2-8"></a>

### Prevalence of geographic atrophy and number affected in Nordic countries

> “Prevalence of GA was estimated to 0.4% (95% confidence intervals [CI]: 0.2%-0.8%), 1.5% (95% CI: 0.7%-2.6%), and 7.6% (95% CI: 4.6%-11.3%) for individuals aged 60-69, 70-79, and 80+ years, respectively. In Nordic countries, we estimate a total of 166 307 individuals with GA in 2023, increasing to 277 893 in 2050.”

Source: [Vangsted et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37680141/)

<a id="topic-2.2.1.2.2-9"></a>

### Prevalence of geographic atrophy in Asian populations

> “The pooled overall prevalence of GA was 1.57 per 1000 persons (95% confidence interval [CI], 1.04-2.10), which was 3 times less than that of neovascular AMD of 5.20 per 1000 persons (95% CI, 3.97-6.43). Compared with those aged 50 to 59 years, the prevalence of GA increased from 0.34 per 1000 persons (95% CI, 0.07-0.62) to 2.90 per 1000 persons (95% CI, 1.55-4.25) in those aged ≥70 years.”

Source: [Rim et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32344073/)

<a id="topic-2.2.1.2.2-10"></a>

### Late AMD in Europe, 2013 to 2040 (geographic atrophy and neovascular AMD combined)

> “Prevalence of early AMD increased from 3.5% (95% confidence interval [CI] 2.1%–5.0%) in those aged 55–59 years to 17.6% (95% CI 13.6%–21.5%) in those aged ≥85 years; for late AMD these figures were 0.1% (95% CI 0.04%–0.3%) and 9.8% (95% CI 6.3%–13.3%), respectively.”
> “This model also displayed that the number of people with late AMD in Europe will increase from 2.7 million in 2013 to 3.9 million by 2040 (Fig 8).”

Source: [Colijn et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5755466/)

<a id="topic-2.2.1.2.2-11"></a>

### Late AMD in Europe among adults aged 60 years and older (geographic atrophy and neovascular AMD combined)

> “Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively.”

Source: [Li et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31712255/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
